UPDATE - DSS’s Impact BioMedical Receives Notice of Allowance from USPTO for Equivir Patent
April 06 2021 - 12:39PM
Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE
American: DSS), a multinational company operating businesses
focusing on brand protection technology, blockchain security,
direct marketing, healthcare, real estate, and securitized digital
assets, today announced its wholly owned subsidiary Impact
BioMedical, Inc. (“Impact BioMedical”) received notice of allowance
(US 16/544,308) from the U.S. Patent and Trademark Office (“USPTO”)
for a method of limiting the occurrence of, reducing the risk or
severity of, or treating Ebola and Rhinovirus using its proprietary
Equivir compound. This allowance is in addition to
Equivir’s previously issued U.S. patent in influenza.
Equivir is designed to work by impeding virulence while also
blocking multiple methods used by viruses to infect and replicate
in host cells, following deployment in a manner similar to a
vitamin. Equivir is a novel blend of FDA Generally Recognized as
Safe (GRAS) eligible polyphenols which have demonstrated antiviral
effects with potential applications as medications or health
supplements.
“This was one of our pending patents for Equivir, and we are
very pleased to have expanded our Impact BioMedical intellectual
property estate with this allowance,” stated Frank D. Heuszel, CEO
of DSS. “With extensive antiviral application potential, Equivir
could provide significant long-term value as we continue to assess
and pursue development and partnering opportunities for this
compound.”
The rhinovirus is the most common viral infectious agent in
humans and is the predominant cause of the common cold. Ebola, also
known as Ebola virus disease (EVD)
or Ebola hemorrhagic fever (EHF), is a rare but
severe, often fatal illness in humans.
Equivir has demonstrated potential effectiveness in in-vitro
studies inhibiting viral infections and SARS COV2.
"Equivir was designed to address emerging viral epidemics and
pandemics. It is specifically created as a broad-spectrum antiviral
for outbreaks such as Influenza. We are continuing our research to
utilize Equivir as an easily deployable strategic defense for viral
infections,” commented Daryl Thompson, Impact BioLife's Director of
Scientific Initiatives and founder of advanced research company
GRDG Sciences, LLC ("GRDG"). Impact BioLife is a wholly owned
subsidiary of Impact BioMedical.
GRDG's Chief Scientific Advisor Dr. Roscoe M. Moore, Jr.,
United States Assistant Surgeon General (Retired) and former
Epidemic Intelligence Service (EIS) Officer at U.S. Center for
Disease Control and Prevention, stated, “As the threat of viral
infections remain significant, the ability for Equivir to be
quickly deployed is a working solution towards global public
health."
Impact BioMedical received its first Equivir patent (US
10,383,842) from the USPTO on August 20, 2019. A third Equivir
patent is pending.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS and
a unique technology source, developer, and business partner in
addressing unmet needs in human healthcare and wellness. For more
information on Impact BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating businesses focused on
brand protection technology, blockchain security, direct marketing,
healthcare, real estate, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman and largest shareholder, Mr. Fai Chan, a
highly successful global business veteran of more than 40 years
specializing in corporate transformation while managing risk. He
has successfully restructured more than 35 corporations with a
combined value of $25 billion.
For more information on DSS
visit http://www.dsssecure.com.
Investor Contact:Dave Gentry, CEORedChip
Companies Inc.407-491-4498Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, but are not limited to,
statements related to the Company's intended use of proceeds and
other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include: risks
relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; risks relating to the results of development
activities; our ability to attract, integrate and retain key
personnel; our need for substantial additional funds; patent and
intellectual property matters; competition; as well as other risks
described in the section entitled "Risk Factors" in the prospectus
and in our other filings with the SEC, including, without
limitation, our reports on Forms 8-K and 10-Q, all of which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations, and
beliefs. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions, or circumstances
on which any such statement is based, except as required by
law.
News powered by iR Direct —
Copyright © 2021 Issuer Direct Corporation.
All Rights Reserved.
DSS (AMEX:DSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Sep 2023 to Sep 2024